4D Molecular Therapeutics’ (FDMT) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report published on Friday morning,Weiss Ratings reports.

A number of other equities analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Bank of America lowered their price objective on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Royal Bank Of Canada lowered their price objective on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. The Goldman Sachs Group lowered their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Finally, Barclays lowered their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.56.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT opened at $3.84 on Friday. The business’s 50 day moving average price is $3.70 and its 200-day moving average price is $4.31. The firm has a market capitalization of $177.91 million, a PE ratio of -1.21 and a beta of 2.84. 4D Molecular Therapeutics has a 1 year low of $2.24 and a 1 year high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. As a group, analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Decheng Capital LLC raised its holdings in shares of 4D Molecular Therapeutics by 0.5% in the 4th quarter. Decheng Capital LLC now owns 400,000 shares of the company’s stock valued at $2,228,000 after buying an additional 2,165 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of 4D Molecular Therapeutics by 7.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company’s stock valued at $247,000 after buying an additional 2,925 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after buying an additional 3,630 shares during the period. Rhumbline Advisers raised its holdings in shares of 4D Molecular Therapeutics by 5.3% in the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock valued at $409,000 after buying an additional 3,675 shares during the period. Finally, ProShare Advisors LLC raised its holdings in shares of 4D Molecular Therapeutics by 30.1% in the 4th quarter. ProShare Advisors LLC now owns 16,369 shares of the company’s stock valued at $91,000 after buying an additional 3,783 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.